Bull & Bear

Bull and Bear

Verdict: Lean Long, Wait For Confirmation - the cyclical case is the stronger read, but the durable revenue-pool question is unresolved and waiting one MCR cycle is the disciplined trade.

Q1 2026 (adjusted EPS $2.35 vs $1.57 consensus, consolidated MCR stepping down from 91.7% to 91.1%) plus the Florida sole-source award and net-positive C-suite buying are the highest-quality datapoints in either deck. They strongly suggest the rate-trend cycle has turned and the moat held during the trough. But management's own FY26 Medicaid MCR guide of 92.9% sits above the FY25 trough, which is exactly what the bear leans on to argue reserves are still being set light. The decisive variable is not whether 2026 EPS recovers — it is whether the post-OBBBA / post-subsidy revenue base normalizes nearer $40B (bear) or $45–50B (bull). Until the Q3 2026 MCR print arrives clean (below 91%) and the FY26 10-K shows no adverse Prior-Period Development, the right posture is constructive but staged.

Bull Case

Bull scenario. ~$260 implied by 13x normalized 2027–2028 adjusted EPS of $20 — a recovery multiple inside the 2018–2019 cycle band (11–12x) and below management's own 2029 target of $25 and BofA's $30 bull case. Disconfirming signals: a Q3 2026 consolidated MCR at or above 92.6% (above 2026 guide), or a second top-5 state contract loss after Virginia.

Bear Case

Bear scenario. ~$120 implied by peer P/B compression to 1.5x on FY26-end equity of ~$4.05B / 51.1M shares (≈$119), cross-checked at 9x normalized post-OBBBA EPS of $13–14 (≈$117–126). Roughly 39% below $198; the 52-week low is $122. Cover signals: two consecutive quarters of consolidated MCR at or below 91.0% combined with CY2027 California or New York state rate notices exceeding 5% trend — i.e., evidence that state actuaries finally over-funded the variable that broke the model.

The Real Debate

Verdict

Lean Long, Wait For Confirmation. Bull carries more weight on the evidence in hand: Q1 2026 already printed inside the bull thesis, Florida sole-source is genuine head-to-head moat proof, insider buying turned net-positive, and the math of a $4.30/share pretax sensitivity to every 100bps of MCR is hard to ignore against a stock trading at trough EPS. The single most important tension is what revenue base the normalized multiple applies to — because that is the durable thesis question, not the cyclical one. The bear could still be right if OBBBA attrition lands closer to the high end (15–20% of Expansion) and 2026 Medicaid rate notices fail to fully close the trend gap, in which case normalized EPS truncates near $13–15 and the right multiple is 9–11x, not 13x. The condition that flips the verdict to Lean Long outright is a Q3 2026 consolidated MCR print below 91.0% combined with a clean FY26 10-K (no adverse Prior-Period Development and no Hindlemann survival of a motion to dismiss on substantive grounds); the durable thesis breaker that flips it to Avoid is post-OBBBA FY27 Medicaid membership disclosure showing attrition tracking to the high end and a Washington RFP loss in 2027.